Modeling tumor development and progression: From PDXs to cancer organoids | A colloquium sponsored by SIRIC ILIAD
On October 18th, the French PDX network and the Organoids research group organised, with the support of the SIRIC ILIAD
Breast cancers: acting on cells in the tumour environment to treat the cancer?
What if acting on the cells surrounding the tumour could improve the effectiveness of treatments? On 14 September 2022, a
SIRIC ILIAD shares its research progress with its partners | SIRIC Review 2018-2022
The SIRIC ILIAD Partners Committee met on Monday 17 October 2022 to present the results of the 5 years of
Teclistamab: a promising new treatment for multiple myeloma
Last August, Professor Philippe Moreau, haematologist and director of SIRIC ILIAD, published a scientific article in the prestigious New England
Welcome to Sara Gandolfi, post-doctoral researcher in cell biology at SIRIC ILIAD!
Since May 2022, Sara Gandolfi has joined the ranks of the SIRIC ILIAD teams as a post-doctoral researcher. She has
Immunotherapy in multiple myeloma: focus on bispecific antibodies
Last June, Professors Philippe Moreau and Cyrille Touzeau, both haematologists and researchers at SIRIC ILIAD, published a scientific article in
